Stop parsing PDFs. Get the API. Request Access

AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Fresenius SE & Co. KGaA

Investor Presentation • Jan 14, 2008

166_ip_2008-01-14_50785b8d-ba9e-469d-b691-dabcf498a5b7.pdf

Investor Presentation

Open in Viewer

Opens in native device viewer

Dresdner Kleinwort German Investment Seminar

January 14 - 16, 2008

Safe Harbor Statement

This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements contained in this presentation.

Achieving Profitable Growth in Attractive Health Care Segments

Fresenius Group: Excellent Sales and Earnings Growth Track Record

1) German GAAP 2) at actual rates: +7 % 3) at actual rates: +12 %

Fresenius Group: Poised for Continued Profitable Growth

  • Leading positions in non-cyclical markets with predictable growth
  • Industry-leading organic growth in all business segments
  • Diversified revenue and earnings base
  • International expansion as key organic growth driver
  • Negligible currency transaction risks due to global production/logistics network
  • Excellent acquisition track record
  • Prudent financial management

Fresenius Kabi

Fresenius Kabi: Leading Market Positions in Infusion Therapy and Clinical Nutrition

  • Focus on organic growth and selective acquisitions
  • Significant growth in emerging markets 5-years sales CAGR (2006)
  • Asia-Pacific: 21 % cc
  • Latin America: 15 % cc
  • State-of-the-art production technologies to ensure cost leadership

Global production and distribution network

Fresenius Kabi: Sales and Earnings Development

Fresenius Kabi: Recent M&A Activity

Strengthen the fast-growing Clinical Nutrition segment:

  • Acquisition of Nestlé's enteral nutrition businesses in France and in Spain

Grow attractive I.V. drug segment:

  • Acquisition of Ribbon – a leading European manufacturer of antibiotic agents

Expand infusion therapy business in Latin America:

  • Acquisition of Sanderson – the Chilean leader in infusion solutions and generic I.V. drugs

Fresenius Kabi: 2007 Financial Outlook Fully Confirmed

Guidance

O
i
r
g
a
n
c
r
e
v
e
n
u
e
h
t
g
r
o
w		 8
%
6
–
E
B
I
T
i
m
a
r
g
n		 %
1
6
0
1
6
5
–

Fresenius Helios / Fresenius Vamed

Fresenius Helios / Fresenius Vamed*: Sales and Earnings Development

* Formerly known as Fresenius ProServe business segment

Fresenius Helios: Top-Tier Private Hospital Operator in Germany

  • Germany is Europe's largest hospital market (> € 60 bn market size)
  • Only 11 % of German acute hospital beds managed by private operators
  • Significant German hospital privatization opportunity
  • Fresenius Helios has a strong track record in hospital operations and acquisitions: targeting 15 % EBITDA margin within 5 years per individual location
  • November 2007: Acquisition of the Krefeld Municipal Hospitals, ~1,200 beds, ~ € 175 m annualized sales

Fresenius Vamed: Engineering and Services for Hospitals and Health Care Facilities

  • Specialized in hospital services from project development to hospital management
  • 430 hospital development projects in 47 countries
  • Management services in 105 hospitals with >30,000 beds
  • Key markets: Europe, Asia-Pacific, Africa

Fresenius Helios / Fresenius Vamed*: 2007 Earnings Outlook Raised

* Formerly known as Fresenius ProServe business segment

Fresenius Biotech

Fresenius Biotech: Attractive Growth Option Based on Proprietary Antibody Technology

  • Malignant ascites dossier dispatched to EMEA end of 2007 as planned
  • Removab® partnering process for North America and Japan ongoing
  • 2007 EBIT outlook of ~ € -50 m confirmed

Fresenius Group: Earnings Outlook 2007 Raised

Mid-term outlook

Attachments

Fresenius Group: Profit and Loss Statement

€
m		 /
Q
3		 /
Q
1
3
-		 /
Q
1
3
2
-		 0
0
7
Y
Y
o		 R
k
e
m
a
r
s
2
0
0
7		 2
0
0
7		 l
t
a
c
a
u
t
r
a
e
s		 t
t
c
o
n
s
a
n
t
r
a
e
s		 /
Q
1
3
2
0
0
7
-
S
l
a
e
s		 2
7
9
8
,		 8
3
9
0
,		 %
7
+		 %
1
1
+
E
B
I
T		 0
4
4		 8
1
1
4
,		 2
%
1
+		 %
1
7
+
l
I
t
t
t
n
e
r
e
s
r
e
s
u		 9
4
-		 2
7
9
-		 %
5
+		 %
0		 %
d
b
8
6
f
i
t
o
e
n
/
f
i
d
h
d
d
t
x
e
e
g
e
r
a
e
s
T
a
e
s
x		 1
1
2
-		 3
2
6
-		 %
4
-		 %
1
0
-		 3
0
%
6
t
t
a
x
r
a
e
N
i
t
e
n
c
o
m
e		 1
0
3		 2
9
8		 2
8
%
+		 3
2
%
+
(
)
(
)
S
f
E
P
€
p
r
e
s		 0
6
6		 1
9
3		 %
2
6
+		 %
3
0
+

Fresenius Group: Cash Flow

€
m		 Q
/
3
2
0
0
7		 Q
/
1
3
2
0
0
7
-		 Q
/
1
3
2
0
0
7
-
Y
Y
o
C
h
f
l
a
s
o
w		 3
0
1		 8
9
2		 9
%
1
+
C
h
i
k
i
i
l
W
t
a
n
g
e
n
o
r
n
g
c
a
p
a		 4
9
+		 2
0
+		 %
1
1
4
+
O
i
C
h
f
l
t
p
e
r
a
n
g
a
s
o
w		 3
5
9		 9
1
2		 %
5
5
+
(
)
C
t
a
p
e
x
n
e		 1
6
8
-		 4
6
5
-		 2
9
%
-
C
h
f
l
a
s
o
w
(
)
b
f
i
i
i
d
d
i
i
d
d
t
e
o
r
e
a
c
q
u
s
o
n
s
a
n
v
e
n
s		 1
9
1		 4
4
7		 %
9
6
+
(
)
i
i
i
A
t
t
c
q
s
o
n
s
n
e
u		 2
0
-		 1
8
2
-		 %
9
4
+
i
i
d
d
D
v
e
n
s		 3
-		 1
9
1
-		 %
2
0
-
F
C
h
f
l
r
e
e
a
s
o
w
(
)
f
i
i
i
d
d
i
i
d
d
t
t
a
e
r
a
c
q
u
s
o
n
s
a
n
v
e
n
s		 1
6
8		 7
4		 1
0
2
%
+

Fresenius Group: Debt and Interest Ratios

Fresenius Group: Double-Digit EBIT Growth in all Business Segments

F
i
r
e
s
e
n
s
u
/
Q
3
2
0
0
1
7
-
d
i
l
C
M
e
c
a
a
r
e		 F
i
r
e
s
e
n
s
u
b
i
K
a		 F
i
r
e
s
e
n
s
u
S
P
r
o
e
r
e
v
S
l
a
e
s
G
h
t
r
o
w		 \$
U
S
7
1
5
1
m
,
%
1
6
+		 €
1
4
9
4
m
,
%
6
+		 €
1
6
0
1
m
,
%
5
+
E
B
I
T
G
h
t
r
o
w		 \$
S
U
1
1
5
2
m
,
1
9
%
+		 €
2
4
2
m
%
1
4
+		 €
1
2
2
m
%
1
6
+

Fresenius Kabi: Strong Sales Growth in Q3/2007 – Fully in Line with Guidance

€
m		 /
Q
1
3
2
0
0
7
–		 /
Q
1
3
2
0
0
6
-		 O
i
r
g
a
n
c
G
h
t
r
o
w
l
S
l
T
t
o
a
a
e
s		 1
4
9
4
,		 1
4
0
4
,		 %
7
d
S
B
P
t
t
r
o
c
e
g
m
e
n
y
u
:
I
f
i
T
h
n
u
s
o
n
e
r
a
p
y		 7
9
3		 7
6
1		 5
%
C
l
i
i
l
i
i
N
t
t
n
c
a
r
o
n
u		 6
1
0		 5
5
5		 %
1
1
T
f
i
T
h
l
r
a
n
s
u
s
o
n
e
c
n
o
o
g
y		 9
1		 8
8		 %
4

Fresenius Kabi: Sales Growth by Region

R
i
l
S
l
e
g
o
n
a
a
e
s
€
m		 /
Q
3
1
-
2
0
0
7		 /
Q
3
1
-
2
0
0
6		 G
h
t
r
o
w		 O
i
r
g
a
n
c
G
h
t
r
o
w
G
e
r
m
a
n
y		 3
2
2		 3
9
1		 %
1		 %
1
E
u
r
o
p
e
G
e
x
e
r
m
a
n
y		 6
8
4		 6
5
0		 %
5		 %
5
A
i
P
i
f
i
s
a
a
c
c
-		 2
2
7		 1
9
0		 %
1
9		 %
2
2
L
i
A
i
t
a
n
m
e
r
c
a		 1
0
5		 9
4		 1
2
%		 1
0
%
R
W
o		 1
5
6		 1
5
1		 %
3		 %
1
0
T
l
l
t
o
a
s
a
e
s		 1
4
9
4
,		 1
4
0
4
,		 %
6		 %
7

Fresenius Kabi: 100 bps EBIT Margin Improvement Compared to Q1-3/2006

€
m		 /
Q
3
2
0
0
1
7
-		 /
Q
3
2
0
0
1
6
-		 C
h
a
n
g
e
E
B
I
T
E
B
I
T
i
m
a
r
g
n		 2
2
4
%
1
6
2		 2
3
1
%
1
5
2		 %
1
4
E
B
I
T
b
R
i
e
g
o
n
y
:
E
r
o
p
e
u
E
B
I
T
i
m
a
r
g
n		 2
1
5
2
%
1
4		 1
8
7
9
3
%
1		 %
1
5
I
i
l
t
t
n
e
r
n
a
o
n
a
E
B
I
T
i
m
a
r
g
n		 8
1
1
6
6
%		 7
2
1
6
6
%		 %
1
3
C
d
C
R
D
t
t
&
o
r
p
o
r
a
e
a
n
o
r
p
o
r
a
e		 5
4
-		 4
6
-		 %
1
7
N
i
t
e
n
c
o
m
e		 1
3
2		 1
0
1		 3
1
%

Fresenius Helios / Fresenius Vamed: On Track to Achieve 2007 Sales Guidance

€
m		 /
Q
1
3
2
0
0
7
-		 /
Q
1
3
2
0
0
6
-		 C
h
a
n
g
e		 O
i
r
g
a
n
c
S
l
a
e
s		 0
1
6
1
,		 2
1
5
6
,		 %
5		 %
1
S
l
b
D
i
i
i
a
e
s
s
o
n
y
v
:
H
i
l
O
i
t
t
(
)
H
l
i
o
s
p
a
p
e
r
a
o
n
s
e
o
s		 1
3
4
8
,		 1
2
0
4
,		 %
1
2		 %
3
E
i
i
S
i
f
n
g
n
e
e
r
n
g
e
r
c
e
s
o
r
v
+
h
i
l
t
(
)
d
h
V
P
t
o
s
p
a
s
a
m
e
a
r
m
a
e
c
+		 2
5
3		 *
3
2
2		 %
2
1
-		 %
7
-
O
d
i
k
E
i
i
t
r
e
r
n
a
e
n
g
n
e
e
r
n
g
b
i
u
s
n
e
s
s		 2
4
5		 2
9
*
1		 %
1
6
-		 2
%
-

* Formerly known as Fresenius ProServe business segment

Fresenius Helios / Fresenius Vamed:

70 bps EBIT Margin Improvement Compared to Q1-3/2006

€
m		 /
Q
3
2
0
0
1
7
-		 /
Q
3
2
0
0
1
6
-		 C
h
a
n
g
e
E
B
I
T
i
E
B
I
T
m
a
r
g
n		 1
2
2
%
7
6		 1
0
5
%
6
9		 1
6
%
E
B
I
T
b
D
i
i
i
y
v
s
o
n
:
H
i
l
O
i
t
t
o
s
p
a
p
e
r
a
o
n
s
i
E
B
I
T
m
a
r
g
n		 1
1
1
%
8
2		 9
4
%
7
8		 8
%
1
E
i
i
S
i
f
h
i
l
t
n
g
n
e
e
r
n
g
e
r
c
e
s
o
r
o
s
p
a
s
v
+
E
B
I
T
i
m
a
r
g
n		 3
1
%
5
1		 *
1
4
%
4
5		 %
7
-
C
t
t
o
r
p
o
r
a
e
c
o
s
s		 2
-		 3
-		 %
3
3

* Formerly known as Fresenius ProServe business segment

Financial Calendar

  • 20.2.2008 Report on Fiscal Year 2007
  • 30.4.2008 Report on 1st quarter 2008
  • 21.5.2008 Annual General Meeting, Frankfurt/Main
  • 30.7.2008 Report on 1st half 2008
  • 4.11.2008 Report on 1st-3rd quarters 2008

Contact

Birgit Grund SVP Investor Relations Fresenius SE

Telephone: +49 6172 608-2485 e-mail: [email protected]

For further information and current news: http://www.fresenius.com

More from Fresenius SE & Co. KGaA

Declaration of Voting Results & Voting Rights Announcements 2025
Nov 17
Declaration of Voting Results & Voting Rights Announcements 2025
Nov 14
Report Publication Announcement 2025
Nov 6
Quarterly Report 2025
Nov 6
Interim / Quarterly Report 2025
Aug 6
Investor Presentation 2025
Aug 6
Declaration of Voting Results & Voting Rights Announcements 2025
Jul 4
Declaration of Voting Results & Voting Rights Announcements 2025
Jun 20
Governance Information 2025
May 23
Quarterly Report 2025
May 7
View all filings →

Talk to a Data Expert

Have a question? We'll get back to you promptly.